Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia

大麻二酚治疗胃轻瘫和功能性消化不良的药效学、药物遗传学、临床疗效和安全性

基本信息

  • 批准号:
    10165708
  • 负责人:
  • 金额:
    $ 37.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-08-01 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Gastroparesis is defined as a gastrointestinal motility disorder with objectively delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis is associated with upper gastrointestinal symptoms including early satiety, postprandial fullness, nausea, vomiting, bloating, and upper abdominal pain. The diagnosis of gastroparesis is based on the combination of symptoms of gastroparesis, absence of gastric outlet obstruction or ulceration, and delay in gastric emptying (4 hour gastric emptying test). Similar symptoms may also accompany other mechanisms of gastric dysfunction including reduced gastric accommodation and gastric hypersensitivity. Together, these gastric motor and sensory abnormalities may cause functional dyspepsia. Functional dyspepsia is a very common cause of substantial morbidity; it is estimated to affect 10% of the population and manifests as abdominal pain/discomfort after eating for at least three days per week. It has been estimated that 40% of patients with this symptom complex consult their physicians, with impact on their workplace attendance and productivity and an economic impact in excess of $18 billion in 2009. Development of effective treatments of these disorders is desirable, given significant unmet medical need. The only approved drug for gastroparesis is metoclopramide, a dopamine D2 antagonist and 5-HT4 agonist; it can be prescribed for a minority of patients for up to 3 months because of endocrine, cardiac and neurological side effects. There is no currently approved treatment for functional dyspepsia. The non-selective cannabinoid receptor agonist, dronabinol, was previously shown to retard gastric emptying and enhance gastric accommodation. Δ9THC and non-pharmaceutical grade cannabidiol are used for diverse pain-related disorders; the effects and benefit-risk ratio of these agents are unclear. With recent FDA approval of cannabidiol, our general hypothesis is that cannabidiol relieves symptoms in patients with gastroparesis and functional dyspepsia without deleterious effects on gastric emptying, accommodation, satiation or satiety. Our aims are: 1. To compare the pharmacodynamics and clinical effects of cannabidiol vs. placebo on satiation, fasting gastric volume, gastric accommodation, gastric emptying, and symptoms in patients with: 1A. gastroparesis (symptoms based on Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD); and 1B. functional dyspepsia (+ non-delayed gastric emptying) and symptoms based on Nepean Dyspepsia Index 2. To assess pharmacogenetics effects of variants in FAAH and CNR1 genes on the pharmacodynamics effects of cannabidiol compared to placebo on fasting and accommodation gastric volumes, gastric emptying and satiation. Anticipated Results and Significance: We expect these studies will lead to understanding the mechanisms of action of cannabidiol in improving gastrointestinal functions and patient reported outcomes, including pain, in patients with gastroparesis or functional dyspepsia, addressing unmet needs of millions of American citizens.
摘要 胃轻瘫是指胃肠道动力障碍,客观上伴有胃排空延迟, 无机械性阻塞。胃轻瘫与上消化道症状有关 包括早饱、餐后饱胀、恶心、呕吐、腹胀和上腹部疼痛。的 胃轻瘫的诊断是基于胃轻瘫的症状、胃出口缺失 阻塞或溃疡,以及胃排空延迟(4小时胃排空试验)。类似的症状可能 还伴随胃功能障碍的其他机制,包括胃适应性降低, 胃过敏总之,这些胃运动和感觉异常可能导致功能性 消化不良功能性消化不良是一个非常常见的原因,大量的发病率,估计影响10% 在人群中,每周至少有三天在进食后表现为腹痛/不适。它 据估计,有40%的这种症状的患者咨询他们的医生, 他们的工作场所出勤率和生产力以及2009年超过180亿美元的经济影响。 鉴于显著未满足的医疗需求,开发这些病症的有效治疗是期望的。的 唯一被批准用于胃轻瘫的药物是甲氧氯普胺,一种多巴胺D2拮抗剂和5-HT 4激动剂;它可以 由于内分泌、心脏和神经方面的原因,少数患者可开具长达3个月的处方 方面的影响.目前尚无获批的功能性消化不良治疗方法。非选择性大麻素 受体激动剂屈大麻酚以前被证明可以延缓胃排空, 住宿.Δ 9 THC和非药用级大麻二酚用于各种疼痛相关疾病; 这些药物的作用和获益风险比尚不清楚。随着最近FDA批准大麻二酚,我们的 一般的假设是大麻二酚缓解胃轻瘫患者的症状, 对胃排空、调节、饱食或饱腹感没有有害影响的消化不良。我们的目标是: 1.比较大麻二酚与安慰剂对饱食、空腹 以下患者的胃容量、胃调节、胃排空和症状: 1A.胃轻瘫(基于胃轻瘫主要症状指数-每日日记(GCSI-DD)的症状);以及 1B.功能性消化不良(+非胃排空延迟)和基于Nehru消化不良指数的症状 2.评估FAAH和CNR 1基因变异体对药效学的药物遗传学影响 与安慰剂相比,大麻二酚对空腹和调节胃容量、胃排空 和饱足感。 预期的结果和意义:我们希望这些研究将有助于了解机制 大麻二酚在改善胃肠道功能和患者报告的结局(包括疼痛)方面的作用, 胃轻瘫或功能性消化不良患者,解决数百万美国公民未满足的需求。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL L. CAMILLERI其他文献

MICHAEL L. CAMILLERI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL L. CAMILLERI', 18)}}的其他基金

A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms
G-POEM 治疗胃轻瘫的随机对照试验,旨在评估可行性、安全性、有效性和生理机制
  • 批准号:
    10843438
  • 财政年份:
    2023
  • 资助金额:
    $ 37.32万
  • 项目类别:
Parkinson Disease Neural Circuitry and Gastrointestinal Pathobiology
帕金森病神经回路和胃肠道病理学
  • 批准号:
    10740119
  • 财政年份:
    2023
  • 资助金额:
    $ 37.32万
  • 项目类别:
Effect of VNS on Gastric Motor Functions
VNS 对胃运动功能的影响
  • 批准号:
    10610561
  • 财政年份:
    2022
  • 资助金额:
    $ 37.32万
  • 项目类别:
Effect of VNS on Gastric Motor Functions
VNS 对胃运动功能的影响
  • 批准号:
    10709641
  • 财政年份:
    2022
  • 资助金额:
    $ 37.32万
  • 项目类别:
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms
G-POEM 治疗胃轻瘫的随机对照试验,旨在评估可行性、安全性、有效性和生理机制
  • 批准号:
    10416023
  • 财政年份:
    2021
  • 资助金额:
    $ 37.32万
  • 项目类别:
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms
G-POEM 治疗胃轻瘫的随机对照试验,旨在评估可行性、安全性、有效性和生理机制
  • 批准号:
    10211000
  • 财政年份:
    2021
  • 资助金额:
    $ 37.32万
  • 项目类别:
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
大麻二酚治疗胃轻瘫和功能性消化不良的药效学、药物遗传学、临床疗效和安全性
  • 批准号:
    9983012
  • 财政年份:
    2019
  • 资助金额:
    $ 37.32万
  • 项目类别:
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
大麻二酚治疗胃轻瘫和功能性消化不良的药效学、药物遗传学、临床疗效和安全性
  • 批准号:
    10404023
  • 财政年份:
    2019
  • 资助金额:
    $ 37.32万
  • 项目类别:
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
大麻二酚治疗胃轻瘫和功能性消化不良的药效学、药物遗传学、临床疗效和安全性
  • 批准号:
    9796963
  • 财政年份:
    2019
  • 资助金额:
    $ 37.32万
  • 项目类别:
Bile Acids, Genetic Control and Colonic Function in Irritable Bowel Syndrome
胆汁酸、遗传控制和肠易激综合症的结肠功能
  • 批准号:
    8536669
  • 财政年份:
    2011
  • 资助金额:
    $ 37.32万
  • 项目类别:

相似海外基金

Disrupted sleep architecture in adolescents with functional abdominal pain disorders
患有功能性腹痛疾病的青少年的睡眠结构被破坏
  • 批准号:
    10641146
  • 财政年份:
    2023
  • 资助金额:
    $ 37.32万
  • 项目类别:
Development and Testing of an Intervention to Facilitate Shared Decision-Making in Pediatric Patients with Abdominal Pain Presenting to the Community Emergency Department Setting
开发和测试一种干预措施,以促进社区急诊科就诊的腹痛儿科患者共同决策
  • 批准号:
    10723374
  • 财政年份:
    2023
  • 资助金额:
    $ 37.32万
  • 项目类别:
Abdominal Pain in Older Patients in Emergency Departments
急诊科老年患者的腹痛
  • 批准号:
    10739136
  • 财政年份:
    2023
  • 资助金额:
    $ 37.32万
  • 项目类别:
Evaluation of abdominal pain after mucosal healing in patients with inflammatory bowel disease -comprehensive analysis of HPA axis-
炎症性肠病患者黏膜愈合后腹痛评价-HPA轴综合分析-
  • 批准号:
    22K16013
  • 财政年份:
    2022
  • 资助金额:
    $ 37.32万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Randomized controlled trial of an internet-based prevention intervention for young children at-risk for functional abdominal pain
针对有功能性腹痛风险的幼儿进行基于互联网的预防干预的随机对照试验
  • 批准号:
    10387725
  • 财政年份:
    2022
  • 资助金额:
    $ 37.32万
  • 项目类别:
Randomized controlled trial of an internet-based prevention intervention for young children at-risk for functional abdominal pain
针对有功能性腹痛风险的幼儿进行基于互联网的预防干预的随机对照试验
  • 批准号:
    10608073
  • 财政年份:
    2022
  • 资助金额:
    $ 37.32万
  • 项目类别:
Novel microbial driven histamine pathways underlying chronic abdominal pain
慢性腹痛背后的新型微生物驱动组胺途径
  • 批准号:
    453255
  • 财政年份:
    2021
  • 资助金额:
    $ 37.32万
  • 项目类别:
    Operating Grants
Home-based transcutaneous electrical acustimulation for abdominal pain
家庭经皮电针治疗腹痛
  • 批准号:
    10619029
  • 财政年份:
    2020
  • 资助金额:
    $ 37.32万
  • 项目类别:
Home-based transcutaneous electrical acustimulation for abdominal pain
家庭经皮电针治疗腹痛
  • 批准号:
    10045379
  • 财政年份:
    2020
  • 资助金额:
    $ 37.32万
  • 项目类别:
Home-based transcutaneous electrical acustimulation for abdominal pain
家庭经皮电针治疗腹痛
  • 批准号:
    10685484
  • 财政年份:
    2020
  • 资助金额:
    $ 37.32万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了